Blis Technologies is heralding a major milestone with
approval for its oral probiotic Blis K12 as a food ingredient
in China.
The approval by the Chinese State Food and Drug
Administration represented the end of a regulatory approval
process that started in 2008.
It enables NZPR Group, which is the commercialisation partner
of the Dunedin-based biotechnology company in China, to
actively market Blis K12 lozenges and associated products
through its distribution networks within the country.
The company was "extremely pleased" with the achievement and
anticipated it would soon be assisting NZPR Group further,
with sales and marketing in China, it said in a statement.
Blis K12 is a natural bacteria, promoted as a probiotic
prevention of upper-airways infection, bacterial sore
throats, tooth and gum disease and chronic bad breath.
Blis Technologies has also announced it will enter into a
market development partnership with Canada-based Integra
Medical, which will produce and sell products in eastern
Europe.
Integra Medical has already successfully achieved regulatory
approval for its first Blis K12-based product as a dietary
supplement within Russia and has embarked on clinical trials
to support its application for its products as an approved
medicine in Russia.
A name, residential address, and (preferably residential) telephone number is required from readers who comment on ODT Online. These details will not be visible to site visitors.